Loading clinical trials...

Study Evaluating ERB-041 in Active Crohn's Disease | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Study Evaluating ERB-041 in Active Crohn's Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Exploratory Pharmacogenomic, Safety and Activity Study of Orally Administered ERB-041 in Subjects With Inflammation Associated With Active Crohn's Disease

NCT00245947•Wyeth is now a wholly owned subsidiary of Pfizer

View on ClinicalTrials.gov

Summary

Evaluate the response of inflammatory serum markers to oral ERB-041 in subjects with inflammation associated with active Crohn's disease.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Men and women, minimum 18 years of age with a diagnosis of Crohn's disease greater than 3 months,
•Eligible subjects must have adequate hematologic, renal, and hepatic function.
•Other inclusions apply

Exclusion Criteria

•Use of the following medications within the specified time period before randomization is prohibited:
•Within 48 hours before randomization
•Nonsteroidal antiinflammatory drugs (NSAIDs) Within 2 weeks before randomization
•Herbal supplements (except for a daily multivitamin/mineral supplement not containing herbal components).
•Other exclusions applies

Key Dates

Start Date

April 1, 2004

Primary Completion Date

April 1, 2005

Completion Date

April 1, 2005

Last Updated

September 10, 2009

Enrollment

ACTUAL participants

Conditions

Crohn's Disease

Interventions

ERB-041

DRUG

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883

Inflammatory Bowel DiseasesCrohn's Disease

View study

RECRUITINGPHASE3

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931

Crohn's Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 10, 2009Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study Evaluating ERB-041 in Active Crohn's Disease

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease

Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas w/ Crohn's Disease